Search research articles
Contact Us
Filters
Showing results (541-550 of 568) with videos related to
Page
of 57
Sort By:
Antibiotics (Basel, Switzerland)
|
June 26, 2026
Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)
Dmitry S Bordin, Dmitrii N Andreev, Sayar R Abdulkhakov, et al.
Gut
|
July 19, 2023
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)
Ángeles Pérez-Aisa, Olga P Nyssen, Alma Keco-Huerga, et al.
Therapeutic Advances in Gastroenterology
|
January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
Gut
|
January 11, 2025
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU
Javier P Gisbert, María G Donday, Sabino Riestra, et al.
Journal of Crohn'S & Colitis
|
August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Diego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
Frontiers in Medicine
|
February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Ana Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology
|
December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU
Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Inflammatory Bowel Diseases
|
September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry
María José Casanova, María Chaparro, Miguel Mínguez, et al.
Journal of Crohn'S & Colitis
|
July 27, 2022
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
Henit Yanai, Anna Kagramanova, Oleg Knyazev, et al.
Journal of Crohn'S & Colitis
|
October 6, 2017
Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease
María José Casanova, Maria Chaparro, Begoña Molina, et al.
Page
of 57
Search research articles
Search
Showing results (541-550 of 568) with videos related to
Sort By:
Page
of 57
Antibiotics (Basel, Switzerland)
|
June 26, 2026
Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)
Dmitry S Bordin, Dmitrii N Andreev, Sayar R Abdulkhakov, et al.
Gut
|
July 19, 2023
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)
Ángeles Pérez-Aisa, Olga P Nyssen, Alma Keco-Huerga, et al.
Therapeutic Advances in Gastroenterology
|
January 8, 2024
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, et al.
Gut
|
January 11, 2025
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU
Javier P Gisbert, María G Donday, Sabino Riestra, et al.
Journal of Crohn'S & Colitis
|
August 1, 2022
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Diego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollón, et al.
Frontiers in Medicine
|
February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Ana Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology
|
December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU
Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Inflammatory Bowel Diseases
|
September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry
María José Casanova, María Chaparro, Miguel Mínguez, et al.
Journal of Crohn'S & Colitis
|
July 27, 2022
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
Henit Yanai, Anna Kagramanova, Oleg Knyazev, et al.
Journal of Crohn'S & Colitis
|
October 6, 2017
Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease
María José Casanova, Maria Chaparro, Begoña Molina, et al.
Page
of 57